PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 2726839

Recent advances in comparative molecular field analysis (CoMFA).

R D Cramer·D E Patterson·J D Bunce
View original source ↗Export metadata ↓

Abstract

Comparative Molecular Field Analysis (CoMFA) has shown predictive performance and versatility that appear to be unprecedented among computer-based techniques for aiding molecular design.

Explore related subjects

Drug DesignEnzyme InhibitorsResearch DesignSerum GlobulinsStructure-Activity RelationshipJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R D Cramer, D E Patterson, J D Bunce. 1989. Recent advances in comparative molecular field analysis (CoMFA).. https://pubmed.ncbi.nlm.nih.gov/2726839/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Strategies to design pyrazolyl urea derivatives for p38 kinase inhibition: a molecular modeling study.

The p38 protein kinase is a serine-threonine mitogen activated protein kinase, which plays an important role in inflammation and arthritis. A combined study of 3D-QSAR and molecular docking has been undertaken to explore the structural insights of pyrazolyl urea p38 kinase inhibitors. The 3D-QSAR studies involved comparative molecular field analysis (CoMFA) and comparative molecular similarity indices (CoMSIA). The best CoMFA model was derived from the atom fit alignment with a cross-validated r (2 )(q (2)) value of 0.516 and conventional r (2) of 0.950, while the best CoMSIA model yielded a q (2) of 0.455 and r (2) of 0.979 (39 molecules in training set, 9 molecules in test set). The CoMFA and CoMSIA contour maps generated from these models provided inklings about the influence of interactive molecular fields in the space on the activity. GOLD, Sybyl (FlexX) and AutoDock docking protocols were exercised to explore the protein-inhibitor interactions. The integration of 3D-QSAR and molecular docking has proffered essential structural features of pyrazolyl urea inhibitors and also strategies to design new potent analogues with enhanced activity.

Drug Design↗